Mortality and hospitalizations among patients enrolled in an interprofessional medication management program

• Verfasst von: Meid, Andreas [VerfasserIn]
• Verfasst von: Wirbka, Lucas [VerfasserIn]
• Verfasst von: Möcker, Robert [VerfasserIn]
• Verfasst von: Ruff, Carmen [VerfasserIn]
• Verfasst von: Weißenborn, Marina [VerfasserIn]
• Verfasst von: Haefeli, Walter E. [VerfasserIn]
• Verfasst von: Seidling, Hanna [VerfasserIn]
• Titel: Mortality and hospitalizations among patients enrolled in an interprofessional medication management program
• Titelzusatz: results of the medicines initiative Saxony–Thuringia (ARMIN)
• Verf.angabe: Andreas D. Meid, Lucas Wirbka, Robert Moecker, Carmen Ruff, Marina Weissenborn, Walter E. Haefeli, Hanna M. Seidling, on behalf of the ARMIN study team
• E-Jahr: 2023
• Jahr: 14 April 2023
• Umfang: 8 S.
• Fussnoten: Das pdf-Dokument umfasst insgesamt 43 Seiten (eMethods, References, Deutsche Fassung) ; Gesehen am 29.05.2024
• Titel Quelle: Enthalten in: Deutsches Ärzteblatt international
• Ort Quelle: Köln : Dt. Ärzte-Verl., 2006
• Jahr Quelle: 2023
• Band/Heft Quelle: 120(2023), 15 vom: Apr., Seite 253-260
• ISSN Quelle: 1866-0452
• DOI: doi:10.3238/arztebl.m2023.0014
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: ADHERENCE
• Sach-SW: BENEFIT
• Sach-SW: CARE
• Sach-SW: DISEASE MANAGEMENT
• K10plus-PPN: 1890254746

Abstract

Background: Measures for improving medication safety in outpatient care are often complex and involve medication reviews. Over the period 2016-2022 (with a preceeding one-year pilot phase), an interprofessional medication management program-the Medicines Initiative Saxony-Thuringia (Arzneimittelinitiative Sachsen-Thuringen, ARMIN)-was implemented in two German federal states. More than 5000 patients received a medication review by the end of 2019 by a team composed of physicians and pharmacists and were provided with joint, continuous care thereafter. Methods: In the framework of a retrospectively registered cohort study, the mortality and hospitalizations of this population (5033 patients) were studied using routine data from a statutory health insurer (observation period 2015-2019) and compared with those of a control group (10 039 patients) determined from the routine data by propensity score matching. Mortality was compared by survival analysis (Cox regression), and hospitalization rates were compared in terms of event probabilities within two years of enrollment in the medication management program. Robustness was tested in multiple sensitivity analyses. Results: Over the observation period, 9.3% of the ARMIN participants and 12.9% of persons in the control group died (hazard ratio of the adjusted Cox regression, 0.84; 95% confidence interval [0.76; 0.94], P = 0.001). In the first two years after inclusion, the ARMIN participants were hospitalized just as often as the persons in the control group (52.4% versus 53.4%; odds ratio from the adjusted model, 1.04 [0.96; 1.11], P = 0.347). The effects were consistent in sensitivity analyses. Conclusion: In this retrospective cohort study, participation in the ARMIN program was associated with a lower risk of death. Exploratory analyses provide clues to the potential origin of this association.